Molecular therapy for Deafness: A therapeutic mix encompassing Clofibrate, Cholecalciferol, Ajoene and DIM (CCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via up regulation of its target genes, 22/April/2018, 11.12 pm
What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Deafness: A therapeutic mix encompassing Clofibrate, Cholecalciferol, Ajoene and DIM (CCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via up regulation of its target genes [easy_payment currency=”USD”] From […]
Molecular therapy for blood-stage Plasmodium infection: Oleic acid, isolated from olive oil, avocado and others, decreases the expression of CTLA-4, PD-L1 and LAG-3, promotes CD4+ T-cell function, increases secretion of protective antibodies, promotes and clear blood-stage malaria via up regulation of its target gene, 22/April/2018, 11.03 pm
Introduction: What they say A study from the Department of Microbiology and Immunology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA shows that “Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4.” This research paper was published, in September 2017 issue of the journal “Nature Medicine” [One of […]
Mechanistic insights into how Brimonidine functions as an anti-glaucoma agent: Brimonidine (trade name: Alphagan and Alphagan-P), used in the treatment of open-angle glaucoma and ocular hypertension, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma, via down regulation of its target gene, 21/April/2018, 8.54 am
Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, […]
Natural product-derived therapy for cardiomyocyte proliferation and heart regeneration: A pharmaceutical mixture encompassing Panaxynol, Triptolide and Sulforaphane (PTS) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 21/April/2018, 8.10am
Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; and Department of Pathology and Laboratory Medicine, University […]
Turning on the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Valsartan, a medication used in the treatment of high blood pressure and congestive heart failure, increases the expression of tumor suppressors genes, such as GRHL3, long ncRNA Gas5, BigH3, TIPE2, PTEN, PDCD4, INK4a, BTG2, TA-p73/p63, TPM1, TIMP3, CCM1/KRIT1 and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 21/April/2017, 8.00 am
From Significance of the study to Public health relevance: Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant […]
Natural product-derived therapy for Malaria: Nordihydroguaiaretic acid (NDGA) increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene, 21/April/2018, 7.40 am
Introduction: What they say: A study from the Section on Human Iron Metabolism, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA shows that “Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk.” This study was published, in the 30 March 2018 issue of […]